ALK inhibitors (Positive control) and ABT199 (Proposed binding) in complex with the ALK active side. حسب Richard Junior Zapata Dongo (17912565)

Comparative Analysis of Hela Cells Cultured under Static Conditions and Exposed to Fluid Shear Stress. حسب Xinyao Zhao (5824427)

Visualization of immune cell infiltration between AD and control group. حسب Wei He (131453)

BCL2 protein keeps their expression in different conditions treatment nevertheless each EML4-ALK cell modells exhibit variable expression. حسب Richard Junior Zapata Dongo (17912565)

Combination therapy exhibited apoptosis in Ba/F3 EML4-ALKmutant cell models. حسب Richard Junior Zapata Dongo (17912565)

miR-1247-3p was downregulated in CRC resistant cells. حسب Dequan Wang (6007007)

The binding energy values of ATP, ALK inhibitors and ABT-199 to ALK were obtained from AlphaFold and modeled protein structures. حسب Richard Junior Zapata Dongo (17912565)

Downregulation of miR-1247-3p inhibited apoptosis and reduced chemosensitivity in cells. حسب Dequan Wang (6007007)

Loewe synergy-antagonism score analysis shows additive and synergistic effects after ALKi and ABT-199 combination treatment. حسب Richard Junior Zapata Dongo (17912565)

miR-1247-3p was downregulated in tissues of patients with CRC and was associated with prognosis and drug resistance. حسب Dequan Wang (6007007)

Overexpression of miR-1247-3p promoted apoptosis and inhibited resistance in drug-resistant cells. حسب Dequan Wang (6007007)

Amino acids interactions and binding energy describe that ABT-199 binds to ALK^Mutant. حسب Richard Junior Zapata Dongo (17912565)

BCL2 antiapoptotic protein exhibits heterogeneous expression in Ba/F3 EML4-ALK^mutants. حسب Richard Junior Zapata Dongo (17912565)

Ba/F3 EML4-ALK^mutants exhibit variable dose-response to ABT-199 treatment. حسب Richard Junior Zapata Dongo (17912565)

Molecular docking showed that ABT-199 can fit into active site of ALK^Mutant. حسب Richard Junior Zapata Dongo (17912565)

Variable evaluation and construction of a prognostic nomogram. حسب Kai Yang (73590)

Coupled gGM and CSF fMRI signal changes induced by a transient hypercapnia challenge. حسب Juliana Zimmermann (10507091)

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout حسب Alper James Alcaraz (20977320)

"…Benchmark concentration analysis of transcriptomic responses at 4 dph, based on the most sensitive transcriptomic features, yielded tPODs between 0.028 and 0.47 μg/L B[<i>a</i>]P. At 28 dph, Cyp1a1 exhibited significantly increased catalytic activity, with biochemical POD, bPOD_EROD,28dph of 0.599 μg/L B[<i>a</i>]P, while morphometric analysis showed significant growth inhibition in terms of length, with apical POD, aPOD_length,28dph of 1.77 μg/L B[<i>a</i>]P, with a notable decreasing trend in body weight. …"

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout حسب Alper James Alcaraz (20977320)

"…Benchmark concentration analysis of transcriptomic responses at 4 dph, based on the most sensitive transcriptomic features, yielded tPODs between 0.028 and 0.47 μg/L B[<i>a</i>]P. At 28 dph, Cyp1a1 exhibited significantly increased catalytic activity, with biochemical POD, bPOD_EROD,28dph of 0.599 μg/L B[<i>a</i>]P, while morphometric analysis showed significant growth inhibition in terms of length, with apical POD, aPOD_length,28dph of 1.77 μg/L B[<i>a</i>]P, with a notable decreasing trend in body weight. …"

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout حسب Alper James Alcaraz (20977320)

"…Benchmark concentration analysis of transcriptomic responses at 4 dph, based on the most sensitive transcriptomic features, yielded tPODs between 0.028 and 0.47 μg/L B[<i>a</i>]P. At 28 dph, Cyp1a1 exhibited significantly increased catalytic activity, with biochemical POD, bPOD_EROD,28dph of 0.599 μg/L B[<i>a</i>]P, while morphometric analysis showed significant growth inhibition in terms of length, with apical POD, aPOD_length,28dph of 1.77 μg/L B[<i>a</i>]P, with a notable decreasing trend in body weight. …"